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Abstract
Background: Recent cancer therapies include drugs that target both tumor growth and angiogenesis including
mammalian target of rapamycin (mTOR) inhibitors. Since mTOR inhibitor therapy is associated with significant side
effects, we examined potential agents that can reduce the therapeutic dose.
Methods: Methylnaltrexone (MNTX), a peripheral mu opioid receptor (MOR) antagonist, in combination with the
mTOR inhibitors temsirolimus and/or rapamycin, was evaluated for inhibition of VEGF-induced human pulmonary
microvascular endothelial cell (EC) proliferation and migration as well as in vivo angiogenesis (mouse Matrigel plug
assay).
Results: MNTX inhibited VEGF-induced EC proliferation and migration with an IC50 of ~100 nM. Adding 10 nM
MNTX to EC shifted the IC50 of temsirolimus inhibition of VEGF-induced proliferation and migration from ~10 nM
to ~1 nM and from ~50 to ~10 nM respectively. We observed similar effects with rapamycin. On a mechanistic
level, we observed that MNTX increased EC plasma membrane-associated tyrosine phosphate activity. Inhibition of
tyrosine phosphatase activity (3,4-dephostatin) blocked the synergy between MNTX and temsirolimus and
increased VEGF-induced tyrosine phosphorylation of Src with enhanced PI3 kinase and mTOR Complex 2-
dependent phosphorylation of Akt and subsequent activation of mTOR Complex 1 (rapamycin and temsirolimus
target), while silencing Src, Akt or mTOR complex 2 components blocked VEGF-induced angiogenic events.
Conclusions: Our data indicate that MNTX exerts a synergistic effect with rapamycin and temsirolimus on
inhibition of VEGF-induced human EC proliferation and migration and in vivo angiogenesis. Therefore, addition of
MNTX could potentially lower the dose of mTOR inhibitors which could improve therapeutic index.
Background
Recent therapeutic interventions for the inhibition of
cancer progression include drugs that target both tumor
growth and angiogenesis. Mammalian target of rapamy-
cin (mTOR) inhibitors, including sirolimus (rapamycin)
and temsirolimus, are potential therapeutic agents for
hepatocellular cancer and renal cell carcinoma due to
their anti-proliferative and anti-angiogenic properties.
However, these mTOR inhibitors are often associated
with unwanted side effects including rash, asthenia,
mucositis, nausea, edema, anemia, hyperglycemia, throm-
bocytopenia, hyperlipaenia and anorexia [1-5]. Therefore,
agents that can reduce the therapeutic concentration of
these drugs could have significant clinical utility. We
recently demonstrated that mu opioid agonists stimulate
VEGF-induced angiogenesis via receptor transactivation
and that mu opioid antagonists can inhibit VEGF recep-
tor signaling [6]. During thec o u r s eo ft h e s ei n v e s t i g a -
tions, we also noted an effect of the peripheral opiate
antagonist methylnaltrexone (MNTX) on endothelial cell
migration and proliferation that occurred beyond the
VEGF receptor, through a mechanism that involves inhi-
bition of Src and Akt. We therefore hypothesized that
methylnaltrexone could have synergistic effects with
anti-angiogenic drugs (i.e. mTOR inhibitors).
In this study, we demonstrate that methylnaltrexone
(MNTX) acts synergistically with the mTOR inhibitors,
rapamycin and temsirolimus, on inhibition of VEGF-
induced angiogenic events. Specifically, MNTX inhibited
EC proliferation with an IC50 of ~100 nM. Adding 10
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liferation from ~10 nM to ~1 nM. Further, adding 10
nM MNTX shifted the IC50 of temsirolimus on inhibi-
tion of EC migration from ~50 nM to ~10 nM. The
synergistic effects of MNTX and temsirolimus were also
demonstrated in an in vivo model of angiogenesis
(mouse Matrigel plug assay). There was a shift in the
IC50 on inhibition of VEGF-induced EC proliferation
and migration with MNTX and rapamycin. The syner-
gistic mechanism involves MNTX activation of tyrosine
phosphatase activity with consequent inhibition of
VEGF-induced Src activation. MNTX-induced Src inac-
tivation results in inhibition of PI3 kinase and mTOR
signaling required for Akt activation (serine/threonine
phosphorylation). These results suggest addition of
MNTX could potentially lower the therapeutic doses of
mTOR inhibitors including rapamycin and temsirolimus.
Methods
Cell Culture and Reagents
Human pulmonary microvascular EC (HPMVEC) were
obtained from Cambrex (Walkersville, MD) and cul-
tured as previously described [7,8] in EBM-2 complete
medium (Cambrex) at 37°C in a humidified atmosphere
of 5% CO2, 95% air, with passages 6-10 used for experi-
mentation. Unless otherwise specified, reagents were
obtained from Sigma (St. Louis, MO). Vascular endothe-
lial growth factor (VEGF) was purchased from R&D Sys-
tems (Minneapolis, MN). Methylnaltrexone bromide or
methylnaltrexone (MNTX) was purchased from Mal-
linckrodt Specialty Chemicals (Phillipsburg, NJ). Temsir-
olimus was acquired through Wyeth Pharmaceuticals.
Rapamycin was purchased from Sigma (St. Louis, MO).
Reagents for SDS-PAGE electrophoresis were purchased
from Bio-Rad (Richmond, CA) and Immobilon-P trans-
fer membrane was purchased from Millipore (Millipore
Corp., Bedford, MA). Rabbit anti-pSer
473Akt, rabbit
anti-pThr
308Akt, rabbit anti-Akt, rabbit anti-pThr
389 p70
S6K and anti-p70 S6K antibodies were purchased from
Cell Signaling Technologies (Danvers, MA). Rabbit anti-
mTOR, rabbit anti-Rictor and rabbit anti-FKBP12 anti-
bodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Mouse anti-pp60src antibody was
purchased from Upstate Biotechnologies (Lake Placid,
NY). LY294002 was purchased from EMD Biosciences
(Gibbstown, NJ). Mouse anti-b-actin antibody, rabbit
anti-phospho-tyrosine
418 Src antibody and naltrexone,
were purchased from Sigma (St. Louis, MO). Secondary
horseradish peroxidase (HRP)-labeled antibodies were
purchased from Amersham Biosciences (Piscataway, NJ).
Immunoprecipitation and Immunoblotting
Cellular materials from treated or untreated HPMVEC
were incubated with IP buffer (50 mM HEPES (pH 7.5),
150 mM NaCl, 20 mM MgCl2,1 %N o n i d e tP - 4 0
(NP-40), 0.4 mM Na3VO4, 40 mM NaF, 50 μMo k a d a i c
acid, 0.2 mM phenylmethylsulfonyl fluoride, 1:250 dilu-
tion of Calbiochem protease inhibitor mixture 3). The
samples were then immunoprecipitated with either anti-
Raptor or anti-Rictor IgG followed by SDS-PAGE in
4-15% polyacrylamide gels, transfer onto Immobilon™
membranes, and developed with specific primary and
secondary antibodies. Visualization of immunoreactive
bands was achieved using enhanced chemiluminescence
(Amersham Biosciences).
Transfection of siRNA against mTOR, Src, Rictor, FKBP12
and Akt
T h es i R N Af o rh u m a nm T O R ,S r c ,R i c t o r ,F K B P 1 2a n d
Akt were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA) and were utilized according to the
manufacturer’s specifications. Briefly, human lung
EC were transfected with siRNA using siPORTamine™
as the transfection reagent (Ambion, TX). Cells (~40%
confluent) were serum-starved for 1 hour followed by
incubated with 250 nM of target siRNA (or scramble
siRNA or no siRNA) for 6 hours in serum-free media.
The serum-containing media was then added (1% serum
final concentration) for 42 h before biochemical experi-
ments and/or functional assays were conducted.
Human Pulmonary Microvascular EC Migration Assay
Twenty-four transwell units with 8 μMp o r es i z ew e r e
used for monitoring in vitro cell migration. HPMVEC
(~1 × 10
4 cells/well) were plated with various treatments
(MNTX, temsirolimus, LY294002, 3,4-Dephostatin or
siRNA) to the upper chamber and VEGF (100 nM) was
added to the lower chamber. Cells were allowed to
migrate for 18 hours. Cells from the upper and lower
chamber were quantitated using the CellTiter96™ MTS
assay (Promega, San Luis Obispo, CA) and read at 492
nm. % migration was defined as the # of cells in the
lower chamber % the number of cells in both the upper
and lower chamber. Each assay was set up in triplicate,
repeated at least five times and analyzed statistically by
Student’s t test (with statistical significance set at
P < 0.05).
Human Pulmonary Microvascular EC Proliferation Assay
For measuring cell growth, HPMVEC [5 × 10
3 cells/well
pretreated with various agents (MNTX, temsirolimus,
LY294002, 3,4-Dephostatin or siRNA) were incubated
with 0.2 ml of serum-free media containing 100 nM
VEGF for 24 h at 37°C in 5%CO2/95% air in 96-well
culture plates. The in vitro cell proliferation assay was
analyzed by measuring increases in cell number using
the CellTiter96™ MTS assay (Promega, San Luis Obispo,
CA) and read at 492 nm. Each assay was set up in
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tistically by Student’s t test (with statistical significance
set at P < 0.05).
Tyrosine Phosphatase Assay
HLMVEC were treated with MNTX (100 nM), VEGF
(100 nM) and/or morphine (100 nM) for 5 minutes.
Lysates were then obtained and further purified to
enrich plasma membrane-associated proteins by wheat
germ agglutinin (WGA) affinity as previously described
[9] and analyzed for tyrosine phosphatase activity using
the fluorometric Rediplate™ 96 EnzChek Tyrosine Phos-
phatase Assay Kit (Invitrogen (Molecular Probes),
Eugene, OR) as we have previously described [10].
Briefly, cellular materials are incubated in reaction buf-
fer at 30°C and then added to a 96 well plate coated
with 6,8-difluoro-4-methylumbelliferyl phosphate
(DiFMUP). Tyrosine phosphatase activity cleaves
DiFMUP into DiFMU with an excitation/emission max-
ima of 358/452 nm.
In Vivo Angiogenesis Assay
The Matrigel plug assay was used to assess in vivo
angiogenesis [11]. 10-week-old female C57BL/6 mice
(Jackson Laboratory, Bar Harbor, ME) were injected
subcutaneously on the ventral abdomen with 500 μl
Matrigel (BD Biosciences, San Jose, CA) containing
either MNTX (100 nM), temsirolimus (10 nM), or both
drugs (100 nM MNTX and 10 nM temsirolimus). 20 ng
VEGF was added to all Matrigel plugs. After 21 days,
the plugs were removed and analyzed for hemoglobin
content. The plugs were weighed and homogenized, and
their hemoglobin content was quantified using the
QuantiChrom™ hemoglobin assay kit (BioAssay Systems,
Hayward, CA).
Results
Analysis of methylnaltrexone (MNTX) synergy with mTOR
inhibitors on inhibition of human endothelial cell (EC)
proliferation and migration
Given our previous published data indicating that
MNTX inhibits VEGF-induced Akt activation [10], we
hypothesized that MNTX could have synergistic effects
with anti-angiogenic drugs that regulate Akt signaling
including mTOR inhibitors. Figure 1-A indicates that
MNTX inhibits EC proliferation with an IC50 of ~100
nM. Adding ten fold lower concentration of MNTX (10
nM) to human EC shifted the IC50 of temsirolimus from
~10 nM to ~1 nM. These results were further confirmed
with isobologram analysis [12] (Figure 1-B). Adding 10
nM MNTX shifted the IC50 of temsirolimus on inhibi-
tion of EC migration from ~50 nM to ~10 nM (Figure 1-
C) and the synergy was confirmed using isobologram
analysis [12] (Figure 1-D). These synergistic effects were
not observed with the uncharged mu opioid antagonist,
naltrexone (Figure 2-A, B; Figure 3-A, B). The synergistic
effects of MNTX were paralleled with the mTOR inhibi-
tor, rapamycin (see Additional Figure 1).
The roles of mTOR Complex components, Akt and Src in
MNTX and temsirolimus inhibition of VEGF-induced
angiogenesis
We next examined the mechanism(s) of the synergistic
effects of MNTX with temsirolimus on inhibition of
VEGF-induced angiogenic events. Our previous pub-
lished data indicate that Akt activation is important in
VEGF-induced angiogenesis [10]. Akt is activated by
threonine phosphorylation (T
308) in the catalytic domain
by PI3 kinase-dependent PDK-1 and by serine phos-
phorylation (S
473) in the hydrophobic motif by various
kinases including mTOR [13-15]. The substrate specifi-
city of mTOR is regulated by complex formation with
other proteins. Specifically, mTOR exists in a rapamy-
cin-sensitive complex (mTOR Complex 1) with the reg-
ulatory-associated protein of mTOR (Raptor) and a
rapamycin-insensitive complex (mTOR Complex 2) with
the rapamycin-insensitive companion of mTOR, Rictor
[1-5,13,15]. We silenced (siRNA) selective proteins in
human EC including mTOR (Figure 4-A). Pre-treating
human EC with MNTX, temsirolimus or mTOR siRNA
followed by VEGF challenge revealed that Akt activation
(serine/threonine phosphorylation) is blocked by
MNTX. Further, silencing mTOR blocked VEGF-
induced serine, but not threonine Akt phosphorylation.
Interestingly, the mTOR inhibitor, temsirolimus, did not
attenuate Akt activation but inhibited the mTOR Com-
plex 1 target p70 S6K [4] (Figure 4-B).
To further investigate the roles of MNTX and temsir-
olimus in VEGF-mediated Akt signaling, we examined
two main mTOR-associated protein complexes, mTOR
Complex 1, consisting of various proteins including
mTOR, FKBP12 (a major target of mTOR inhibitors
including temsirolimus) and Raptor, and mTOR Com-
plex 2, consisting of various proteins including SIN1
and Rictor. Immunoprecipitation with either Rictor or
Raptor antibody after VEGF treatment of human EC
with MNTX or temsirolimus pre-treatment indicated
that VEGF induces mTOR Complex 1 and mTOR Com-
plex 2 formation. Both MNTX and temsirolimus block
mTOR Complex 1 formation while only MNTX blocks
mTOR Complex 2 formation (Figure 5-A).
We and others have previously published that VEGF
induces Src and PI3 kinase activation in human EC
[6,16,17]. We inhibited PI3 kinase activity with LY294002
or silenced (siRNA) Src or Rictor (required for mTOR
Complex 2 formation), challenged EC with VEGF and
examined Akt activation. Our results (Figure 5-B) indi-
cate that Src is required for both serine and threonine
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required for threonine phosphorylation of Akt and
mTOR Complex 2 is required for serine phosphorylation
of Akt.
Similar to our results in Figures 4 and 5, we observed
t h a ts i l e n c i n g( s i R N A )o fm T O R ,A k t ,S r c ,R i c t o ro r
inhibition of PI3 kinase activity significantly attenuated
VEGF-induced human EC proliferation (Figure 6-A) and
migration (Figure 6-B) with Src silencing inducing the
greatest inhibition of these activites. In addition, silen-
cing Src or FKBP12 (direct target of temsirolimus
[2,3,5]) blocked the synergy observed with MNTX and
temsirolimus on VEGF-induced EC proliferation (Figure
6-C) and migration (Figure 6-D). However, our syner-
gism analysis is complicated by the potent effects of Src
and FKBP12 silencing alone.
The role of tyrosine phosphatase activity in MNTX and
temsirolimus inhibition of VEGF-mediated angiogenesis
Our previous studies indicate that MNTX attenuates
VEGF-induced pp60 Src activation (tyrosine phosphory-
lation) [6,10]. One possible mechanism of attenuating
Src tyrosine phosphorylation is through tyrosine phos-
phatase activity [18,19]. To investigate this, we measured
EC plasma membrane-associated tyrosine phosphatase
activity and discovered that VEGF and morphine inhibit,
Figure 1 Determination of methylnaltrexone (MNTX) synergistic effects with temsirolimus on inhibition of VEGF-induced human
endothelial cell (EC) proliferation and migration. Panel A: Graphical representation of human EC assayed for VEGF (100 nM)-induced
proliferation (24 hours) in the presence or absence of 0.1, 1.0, 10, 100 or 500 nM MNTX, temsirolimus, or temsirolimus + 10 nM MNTX.
Experiments were performed in triplicate. Error bars = standard deviation. Panel B: Isobologram analysis of the combination of MNTX and
temsirolimus on inhibition of VEGF-induced proliferation. The dashed line indicates a zero interaction for the isobole. The shift to the left
indicates a synergistic interaction. Panel C: Graphical representation of human EC assayed for VEGF (100 nM)-induced migration (24 hours) in the
presence or absence of 0.1, 1.0, 10, 100 or 500 nM MNTX, temsirolimus, or temsirolimus + 10 nM MNTX. Experiments were performed in
triplicate. Error bars = standard deviation. Panel D: Isobologram analysis of the combination of MNTX and temsirolimus on inhibition of VEGF-
induced migration. The dashed line indicates a zero interaction for the isobole. The shift to the left indicates a synergistic interaction.
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(Figure 7-A). Treated of human EC with the potent tyr-
osine phosphatase inhibitor, 3.4-dephostatin [20]
blocked MNTX inhibition of VEGF-induced Src and
Akt activation (Figure 7-B) and reversed MNTX syner-
gistic effects with temsirolimus on VEGF-induced prolif-
eration (shift in the IC50 from ~1 nM to ~20 nM,
Figure 7-C) and VEGF-induced migration (shift in the
IC50 from ~5 nM to ~70 nM, Figure 7-D).
In vivo analysis of MNTX synergy with temsirolimus on
inhibition of angiogenesis
Considering the results of our in vitro human EC stu-
d i e s ,w en e x te x a m i n e dt h er o l eo fM N T Xa n d
temsirolimus on angiogenesis in vivo. In the mouse
Matrigel plug assay [11], addition of 100 nM MNTX
inhibited angiogenesis (Figure 8). Importantly, addition
of MNTX in combination with temsirolimus inhibited
angiogenesis to a greater extent than either drug alone
(Figure 8). These results indicate MNTX and temsiroli-
mus have a synergistic effect on inhibition of angiogen-
esis in vivo.
Discussion
We and others have previously noted an effect of opi-
ates on endothelial cell migration and proliferation, and
an effect of opiate antagonists in attenuating opiate
induced angiogenesis [6,8,10]. The selective peripheral
Figure 2 Comparison of MNTX and naltrexone on synergy with temsirolimus on VEGF-induced angiogenic events. Panel A: Bar graph
representation of human EC assayed for VEGF (100 nM)-induced proliferation (24 hours) in the presence or absence of 10 nM MNTX, 100 nM
MNTX, 10 nM naltrexone, 10 nM temsirolimus, 100 nM morphine + 10 nM temsirolimus, 10 nM MNTX + 10 nM temsirolimus, 100 nM MNTX +
10 nM temsirolimus or 10 nM naloxone + 10 nM temsirolimus. Experiments were performed in triplicate. Error bars = standard deviation. Panel
B: Bar graph representation of human EC assayed for VEGF (100 nM)-induced migration (24 hours) in the presence or absence of 10 nM MNTX,
100 nM MNTX, 10 nM naltrexone, 10 nM temsirolimus, 100 nM morphine + 10 nM temsirolimus, 10 nM MNTX + 10 nM temsirolimus, 100 nM
MNTX + 10 nM temsirolimus or 10 nM naloxone + 10 nM temsirolimus. Experiments were performed in triplicate. Error bars = standard
deviation.
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tered subcutaneously, is approved in the USA, EU,
Canada and Australia. In the USA, it is indicated for the
treatment of opioid-induced constipation in patients
with advanced illness (i.e. cancer, AIDS) who are receiv-
ing palliative care, when responses to laxatives have not
been sufficient [21-24]. Use in attenuating other side
effects of opiates has been studied [25]. In this study, we
present the novel findings that MNTX acts in a syner-
gistic manner with the mTOR inhibitors, rapamycin and
temsirolimus, in inhibiting VEGF-induced angiogenic
events. Our results indicate that the synergistic effects of
MNTX with mTOR inhibitors are achieved through
inhibition of different components of a common VEGF-
induced angiogenic signaling pathway. MNTX inhibits
the mu opioid receptor and stimulates tyrosine phos-
phatase activity which inhibits VEGF-induced Src activa-
tion and Src-regulated PI3 kinase and mTOR Complex
2-mediated Akt activation. Temsirolimus and rapamycin
inhibit the downstream target of activated Akt, mTOR
Figure 3 Isobologram analysis indicating a lack of synergy of naltrexone with temsirolimus on VEGF-induced human EC proliferation
and migration. Panel A: Isobologram analysis of the combination of naltrexone and temsirolimus on inhibition of VEGF-induced proliferation.
The dashed line indicates a zero interaction for the isobole. The close proximity of the data with the dashed line indicates there is not a
synergistic interaction. Panel B: Isobologram analysis of the combination of naltrexone and temsirolimus on inhibition of VEGF-induced
migration. The dashed line indicates a zero interaction for the isobole. The close proximity of the data with the dashed line indicates there is not
a synergistic interaction.
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motes synergistic inhibition of VEGF-induced angiogen-
esis (Figure 9). Therefore, we hypothesize that, in
addition to its effects on GI motility, MNTX might have
clinical utility by potentially lowering the therapeutic
doses of mTOR inhibitors in the treatment of various
diseases requiring angiogenesis including cancer.
We have focused our studies on methylnaltrexone
(MNTX) because it is more likely to be used in
advanced illness clinical settings than tertiary mu opioid
receptor antagonists. Uncharged mu opioid antagonists,
including naloxone and naltrexone, are fairly lipid
soluble and cross the blood-brain barrier easily [27-29].
Despite numerous attempts at regulating doses, mu
opioid antagonists have proven unsuitable for patients
receiving opiates for pain management because of
analgesia reversal and breakthrough pain [30]. MNTX is
a quaternary derivative of the tertiary mu opiate antago-
nist naltrexone [31]. The addition of the methyl group
to naltrexone at the amine in the ring forms the com-
pound N-methylnaltrexone with greater polarity and
lower lipid solubility. Because MNTX does not cross the
blood-brain barrier, it could play a therapeutic role in
reversing the peripheral effects of opiates in palliative
Figure 4 Analysis of MNTX, temsirolimus and mTOR regulation of VEGF-induced Akt activation in human EC. Panel A: Human EC were
either untreated (control) or treated with scramble siRNA, mTOR siRNA, Src siRNA, Rictor siRNA or Akt siRNA for 48 hours, lysates obtained, run
on SDS-PAGE and immunoblotted with anti-mTOR (a), anti-Src (b), anti-Rictor (c), anti-Akt (d) or anti-actin (e) antibody. Panel B: Human EC were
serum starved for one hour and either untreated (control) or treated with VEGF (100 nM, 5 minutes) with or without pretreatment (1 hour) with
100 nM MNTX, 100 nM temsirolimus, or pretreatment for 48 hours with mTOR siRNA. EC lysates were obtained, run on SDS-PAGE and
immunoblotted with anti-pSer
473Akt (a), anti-pThr
308Akt (b), anti-AKT (c), anti-pThr389 p70 S6K (d) or anti-p70 S6K (e) antibody.
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Page 7 of 14Figure 5 Determination of mTOR Complex 1 and mTOR Complex 2 regulation of VEGF-induced Akt activation in human EC. Panel A:
Human EC were serum starved for one hour and either untreated (control) or treated with VEGF (100 nM, 5 minutes) with or without
pretreatment (1 hour) with 100 nM MNTX or 100 nM temsirolimus. EC were then solublized in IP buffer (50 mM HEPES (pH 7.5), 150 mM NaCl,
20 mM MgCl2, 1% Nonidet P-40 (NP-40), 0.2 mM phenylmethylsulfonyl fluoride, 1:250 dilution of Calbiochem protease inhibitor mixture 3) and
immunoprecipitated with either anti-Raptor (mTOR Complex 1 component) or anti-Rictor (mTOR Complex 2 component) antibody. The
immunoprecipitated material was run on SDS-PAGE and immunoblotted with anti-mTOR (a, d), anti-FKBP12 (mTOR Complex 1 component and
direct target of temsirolimus) (b), anti-Raptor (c), anti-SIN1 (mTOR Complex 2 component) (e) or anti-Rictor (f) antibody. Panel B: Human EC were
serum starved for one hour and either untreated (control) or treated with VEGF (100 nM, 5 minutes) with or without pretreatment (1 hour) with
LY294002 (PI3 kinase inhibitor, 10 μM) or pretreated for 48 hours with Src or Rictor (mTOR Complex 2 component) siRNA. EC lysates were
obtained, run on SDS-PAGE and immunoblotted with anti-pSer
473Akt (a), anti-pThr
308Akt (b), or anti-AKT (c) antibody.
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Page 8 of 14Figure 6 T h ee f f e c t so fm T O R ,A k t ,S r c ,R i c t o ra n dP I 3k i n a s eo nV EGF-induced human EC proliferation and migration. Panel A:B a r
graph representation of human EC assayed for VEGF (100 nM)-induced proliferation (24 hours) in the presence or absence of 48 hour
pretreatment with mTOR siRNA, Akt siRNA, Src siRNA, Rictor (mTOR Complex 2 component) siRNA or pretreatment (1 hour) with LY294002 (PI3
kinase inhibitor, 10 μM). Experiments were performed in triplicate. Error bars = standard deviation. Panel B: Bar graph representation of human
EC assayed for VEGF (100 nM)-induced migration (24 hours) in the presence or absence of 48 hour pretreatment with mTOR siRNA, Akt siRNA,
Src siRNA, Rictor (mTOR Complex 2 component) siRNA or pretreatment (1 hour) with LY294002 (PI3 kinase inhibitor, 10 μM). Experiments were
performed in triplicate. Error bars = standard deviation. Panel C: Bar graph representation of human EC assayed for VEGF (100 nM)-induced
proliferation (24 hours) in the presence or absence of 48 hour pretreatment with Src or FKBP12 siRNA with addition of 100 nM MNTX and/or 10
nM temsirolimus. Experiments were performed in triplicate. Error bars = standard deviation. Panel D: Bar graph representation of human EC
assayed for VEGF (100 nM)-induced migration (24 hours) in the presence or absence of 48 hour pretreatment with Src or FKBP12 siRNA with
addition of 100 nM MNTX and/or 10 nM temsirolimus. Experiments were performed in triplicate. Error bars = standard deviation.
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Page 9 of 14Figure 7 3,4-Dephostatin inhibition of tyrosine phosphatase activity blocks MNTX synergistic effects with temsirolimus on inhibition
of VEGF-induced angiogenic events. Panel A: Bar graph representation of human EC plasma membrane-associated tyrosine phosphatase
activity (see Methods) with VEGF (100 nM), morphine (100 nM), MNTX (100 nM) or combination treatment. The asterisks indicate a statistically
significant difference (p < 0.05) between control and drug challenge. In addition, there is a statistically significant difference (p, 0.05) between
without MNTX and with MNTX treatment. Panel B: Bar graph representation of the ration of phospho-protein to total protein using immunoblot
analyses of pSer
473Akt, pThr
308Akt and pTyr
418Src of human EC treated with 100 nM VEGF with or without 10 nM or 100 nM MNTX in the
presence or absence of the tyrosine phosphatase inhibitor, 3,4-dephostatin (50 μM). Experiments were performed in triplicate. Error bars =
standard deviation. Panel C: Graphical representation of the 50% inhibition concentration (IC50, (nM)) of human EC assayed for VEGF (100 nM)-
induced proliferation (24 hours) of temsirolimus with or without 10 nM MNTX in the presence or absence of the tyrosine phosphatase inhibitor,
3,4-dephostatin (50 μM). Experiments were performed in triplicate. Error bars = standard deviation. Panel D: Graphical representation of the 50%
inhibition concentration (IC50, (nM)) of human EC assayed for VEGF (100 nM)-induced migration (24 hours) of temsirolimus with or without 10
nM MNTX in the presence or absence of the tyrosine phosphatase inhibitor, 3,4-dephostatin (50 μM). Experiments were performed in triplicate.
Error bars = standard deviation.
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Page 10 of 14Figure 8 In vivo analysis of MNTX synergy with temsirolimus on inhibition of angiogenesis. In Panels A and B, 10-week-old female
C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME) were injected subcutaneously on the ventral abdomen with 500 μl Matrigel (BD Biosciences,
San Jose, CA) containing either MNTX (100 nM), temsirolimus (10 nM), or both drugs (100 nM MNTX and 10 nM temsirolimus). 20 ng VEGF was
added to all Matrigel plugs. After 21 days, the plugs were removed. Panel A: Pictures of Matrigel plugs after removal from mice. Panel B:
Graphical analysis of Matrigel plug hemoglobin content. The plugs were weighed and homogenized, and their hemoglobin content was
quantified using the QuantiChrom™ hemoglobin assay kit (BioAssay Systems, Hayward, CA), n = 3 per group. The asterisks indicate a statistically
significant difference (p < 0.05) between treatment and control. There is also a statistically significant difference (p < 0.05) between MNTX or
temsirolimus treatment alone versus in combination.
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for analgesia [32-37]. The plasma concentrations of
morphine and MNTX in patients after parenteral or
oral administration are consistent with the levels that
regulated synergistic inhibition of VEGF-induced angio-
genesis and inhibited Src in our in vitro model (IC50 =
~10 nM) [10].
We focused our studies on temsirolimus and rapamy-
cin based on our previous published data that MNTX
regulates VEGF-induced Akt activation [10] and the
intricate relationship between Akt and mTOR pathways
[5,26]. Both rapamycin and temsirolimus, a soluble ester
analog of rapamycin, exert their action by binding to the
intracellular protein, FKBP12, and inhibiting mTOR
Complex 1 formation [38-40]. However, mTOR can still
complex with SIN1 and Rictor (mTOR Complex 2)
[1,15,26]. The mTOR Complex 2 serine phosphorylates
Akt and is involved in actin cytoskeletal regulation
[2,4,14,41,42]. Akt can also be threonine phosphorylated
by PI3 kinase activation of PDK1 [41-45]. Activated (ser-
ine/threonine phosphorylated) Akt promotes mTOR
Complex 1 assembly through inactivation (phosphoryla-
tion) of TSC2 and PRAS40 [5,26]. Activated mTOR
Complex 1 phosphorylates several target proteins
Figure 9 Schematic diagram of a proposed mechanism of MNTX synergistic effects with temsirolimus on inhibition of VEGF-induced
angiogenic events. VEGF binding to VEGF receptors (1) induces Src activation (tyrosine phosphorylation)(2), Src-mediated PI3 kinase/PDK1
activation with consequent phospho-threonine
308 Akt phosphorylation (3) and mTOR Complex 2 formation (mTOR/SIN1/Rictor) with consequent
phospho-serine
473 Akt phosphorylation (4). Activated (serine/threonine phosphorylated) Akt promotes mTOR Complex 1 formation (mTOR/
FKBP12/Raptor) (5) required for EC proliferation and migration (6). MNTX inhibits the mu opioid receptor and promotes tyrosine phosphatase
activity and Src inactivation (7). Temsirolimus binds to FKBP12 and inhibits mTOR Complex 2 formation (8). Therefore, the synergistic effects of
MNTX with temsirolimus are achieved through inhibition of different components of a common VEGF-induced angiogenic signaling pathway.
MNTX can have important clinical utility by potentially lower the therapeutic dose of temsirolimus in the treatment of various diseases requiring
angiogenesis including cancer.
Singleton et al. Journal of Angiogenesis Research 2010, 2:5
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Page 12 of 14including S6K and 4EBP1 involved in cell proliferation,
growth and survival [1,2,4,5,26].
T h ee f f e c t so fM N T Xo ni n h i b i t i o no fm T O R
described in this manuscript go beyond VEGF receptor
activation and extend to downstream signaling path-
ways. We and others have previously reported that inhi-
bition of Src protects from EC barrier disruption and
angiogenesis [6,8,10]. Src regulates several potential
angiogenic events including EC contraction and vascular
permeability [43,44]. We extended these finding by
observing that Src regulates VEGF-induced, PI3 kinase
and mTOR-dependent, serine/threonine phosphoryla-
tion of Akt important for EC proliferation and migra-
tion. Further, Src regulates the synergistic effects of
MNTX with temsirolimus on inhibition of VEGF-
induced angiogenic events. We have previously demon-
strated that MNTX increases tyrosine phosphatase activ-
ity, including RPTPμ [10]. This study extends these
finding by demonstrating that the potent protein tyro-
sine phosphatase inhibitor, 3,4-Dephostatin, blocks
MNTX inhibition of VEGF-induced Src and Akt phos-
phorylation. 3,4-Dephostatin is known to block the
phosphatase activity of PTP-1B, SHPTP-1 and CD45
[20,40,46-48]. In addition, 3,4-Dephostatin increased
insulin-induced tyrosine phosphorylation of PLCg,c - C b l
and the regulatory subunit of PI3 kinase (a known Src
substrate) [48]. We are currently examining the role of
these tyrosine phosphatases in MNTX inhibition of
VEGF-induced Src activation and angiogenesis.
Temsirolimus was approved by the FDA in 2007 for
the treatment of advanced renal cell carcinoma, a dis-
ease resistant to existing chemotherapies (IFN-a,I L - 2 )
[3,38-40]. There have been other attempts to potentiate
the action of temsirolimus. In Phase 3 clinical trails,
temsirolimus, IFN-a or temsirolimus + IFN-a treatment
resulted in median survival rates of 10.9 months, 7.3
months and 8.4 months, respectively [3,38-40]. IFN-a
did not augment temsirolimus treatment alone
[3,38-40]. The results of these clinical trials indicate the
need for an effective drug in temsirolimus combination
therapy. Our observations that MNTX acts synergisti-
cally with mTOR inhibitors on inhibition of VEGF-
induced angiogenic events merit clinical studies.
Conclusions
Our results indicate that MNTX exerts a synergistic
effect with rapamycin and temsirolimus on inhibition of
VEGF-induced human EC proliferation and migration
and in vivo angiogenesis. These synergistic effects are
achieved through inhibition of different components of
a common VEGF-induced angiogenic signaling pathway.
MNTX inhibits the mu opioid receptor and stimulates
tyrosine phosphatase activity which inhibits VEGF-
induced Src activation and Src-regulated PI3 kinase and
mTOR Complex 2-mediated Akt activation. Temsiroli-
mus and rapamycin inhibit the downstream target of
activated Akt, mTOR Complex 1. Inhibition of these
events promotes synergistic inhibition of VEGF-induced
angiogenesis (Figure 9). Therefore, addition of MNTX
could potentially lower the dose of mTOR inhibitors
which could improve therapeutic index.
Additional file 1: Determination of methylnaltrexone (MNTX)
synergistic effects with rapamycin on inhibition of VEGF-induced
human endothelial cell (EC) proliferation and migration. This file
shows through inhibition curves and isobologram analysis that MNTX
acts synergistically with the mTOR inhibitor, rapamycin, on inhibition of
VEGF-induced angiogenic events.
Click here for file
[http://www.biomedcentral.com/content/supplementary/2040-2384-2-5-
S1.PDF]
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